

# **Announcement Summary**

# **Entity name**

UNIVERSAL BIOSENSORS INC.

# Date of this announcement

Tuesday October 08, 2024

# The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
UBIAAC	PERFORMANCE RIGHTS	750,000	01/10/2024

Refer to next page for full details of the announcement



# Part 1 - Entity and announcement details

# 1.1 Name of entity

UNIVERSAL BIOSENSORS INC.

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

# 1.2 Registered number type

Registration number

ARBN

121559993

#### 1.3 ASX issuer code

UBI

#### 1.4 The announcement is

New announcement

#### 1.5 Date of this announcement

8/10/2024



Part 2 - Issue details

- 2.1 The +securities the subject of this notification are:
- +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX
- 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

#### ASX +security code and description

**UBIAAC: PERFORMANCE RIGHTS** 

Date the +securities the subject of this notification were issued

1/10/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

2 tranches of Performance Rights (PR) are to be issued as part of a long-term incentive plan to an employee of UBI.

Tranche 1 (T1) - 0.50M PR to be issued.

Tranche 2 (T2) - 0.25M PR to be issued.

Grant date is 1 October 2024 and the PR expire on 24 Mar 2025. If the vesting conditions in respect of PR are not met by the expiry date, those PR will lapse. Where the employee resigns or is terminated or otherwise ceases employment for any reason prior to the vesting date, all unvested PR will immediately lapse unless otherwise determined by the Board.

#### Any other information the entity wishes to provide about the +securities the subject of this notification

#### Vesting conditions:

- T1 (a) Mkt cap equal to or greater than \$300M (for any single days trading of UBI CDI/shares for any cumulative, non-consecutive or otherwise, 180 days; or (b) Revenue for any 3 consecutive or non-consecutive 3 month period exceeds \$5M for each 3 month period. For the avoidance of doubt \$15M of in market revenue for any 9 month period will trigger this vesting condition; or (c) UBIs operating cash inflow from ordinary activities equals or exceeds a cumulative \$9M for any consecutive 9 month period; or (d) Where there is a change of control of equal to or greater than 50% of UBI CDI/shares subject to in a takeover, scheme of arrangement, corporate restructure or other transaction.
- T2 Where there is a change of control of equal to or greater than 50% of UBI CDI/shares subject to in a takeover, scheme of arrangement, corporate restructure or other transaction of value greater than \$500M (but a lower change of control can be subject to Board approval).

Issue details

Number of +securities

750,000



#### Part 4 - +Securities on issue

# Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

# 4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

# ASX +security code and description UBI : CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB 298,067,435 UBIO : OPTION EXP 08-MAY-27 US PERSON PROHIBITED EXCL QIB 97,182,901

#### 4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
UBIAAC : PERFORMANCE RIGHTS	7,500,000
UBIAAE : OPTION EXPIRING 26-MAY-2025 EX \$0.92	1,920,000
UBIAAF : OPTION EXPIRING 26-MAY-2025 EX \$1.00	1,920,000
UBIAAA : OPTION EXPIRING 24-MAR-2025 RESTRICTED	500,000
UBIAR : OPTION EXPIRING 24-MAR-2025 EX 30C	2,364,667
UBIAP : OPTION EXPIRING 24-MAR-2025 EX 25C	2,364,667
UBIAAG : PERFORMANCE SHARES	1,725,000



# Part 5 - Other Listing Rule requirements

- 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?  $N_{\rm O}$
- 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

  No
- 5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
  Yes
- 5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

750,000 Performance Rights

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? N/A